Evaluating point-of-care testing for Hepatitis C in Australia
Official title: The National Australian HCV Point-of-Care Testing Program: An Observational Cohort Study to Evaluate the Use of Finger-stick Point-of-care Hepatitis C Testing to Enhance Diagnosis and Treatment of HCV Infection - Minimal Dataset
Run by Kirby Institute · NCT05248555 · Data updated 2026-11-12
This study is testing if quick finger-stick tests for Hepatitis C can help people in high-risk areas in Australia get diagnosed and treated more easily.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80000 (estimated) |
| Sponsor | Kirby Institute Government |
| Locations | 16 sites (Sydney, New South Wales and 15 other locations) |
| Status | Recruiting |
| Started | January 23, 2023 |
| Main results expected | December 2029 |
| Study ends | December 2029 |
| Registry record updated | September 28, 2026 |
| Trial ID | NCT05248555 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this program are individuals aged 18 and older who are at risk for Hepatitis C and willing to undergo point-of-care testing.
✕Probably not a fit
Patients who are not at risk for Hepatitis C or those who have already been diagnosed and treated may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort program aims to assess the impact of finger-stick point-of-care testing on the diagnosis and treatment of Hepatitis C (HCV) infection in Australia. Participants will be recruited from various high-risk settings, including drug treatment clinics and prisons, where they will undergo HCV testing. The study will collect data on participants who test positive for HCV RNA, linking them to standard care for treatment. The initiative seeks to improve treatment uptake and contribute to the goal of HCV elimination by 2030.
Why it matters
Potential benefit: If successful, this program could significantly increase the diagnosis and treatment rates of Hepatitis C, ultimately reducing the disease burden.
How similar studies have gone: Previous studies have shown success with point-of-care testing interventions for Hepatitis C, indicating a promising approach to increasing diagnosis and treatment.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years of age. * Received point-of-care HCV testing. Exclusion Criteria: * Nil
Where it's running
-
Maryborough Correctional Centre
Aldershot, Queensland, Australia Recruiting -
QuIHN
Brisbane, Queensland, Australia Recruiting -
Lotus Glen Correctional Centre
Cairns, Queensland, Australia Recruiting -
West Moreton Hospital and Health Service
Ipswich, Queensland, Australia Recruiting -
Townsville Correctional Centre
Townsville, Queensland, Australia Recruiting -
Woodford Correctional Centre
Woodford, Queensland, Australia Recruiting
Show 10 more locations
-
Hepatitis SA
Hackney, South Australia, Australia Recruiting -
Mount Gambier Priosn
Mount Gambier, South Australia, Australia Recruiting -
Medically Supervised Injecting Room
Melbourne, Victoria, Australia Recruiting -
Dame Phyllis Frost Centre
Ravenhall, Victoria, Australia Recruiting -
Geo Healthcare - The Geo Group Australia Pty Ltd
Ravenhall, Victoria, Australia Recruiting -
Justice Health and Forensic Mental Health Network
Sydney, New South Wales, Australia Active not recruiting -
Hepatitis Queensland
Coorparoo, Queensland, Australia Completed -
Palen Creek Correctional Centre
Rathdowney, Queensland, Australia Not yet recruiting -
South Australian Prison Health Service
Marden, South Australia, Australia Not yet recruiting -
St Vincent's Correctional Health Services
Fitzroy, Victoria, Australia Active not recruiting
Study contacts
- Study coordinator: David Silk, BSc
- Email: dsilk@kirby.unsw.edu.au
- Phone: +61293850900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Glecaprevir/pibrentasvir started during pregnancy for women with hepatitis C, with or without HIV
This trial will test whether taking glecaprevir/pibrentasvir during pregnancy is safe and how the drug is processed in pregnant women who have hepatitis C, including those who also have HIV, and will follow their infants for 10 weeks after birth.
-
Evaluating hepatitis C treatment during pregnancy
This study tests how well a new hepatitis C treatment works for pregnant adults with a history of drug use and looks at their experience during the treatment.
-
Decentralized treatment for hepatitis C in Brazil
This study is testing a new way to treat hepatitis C in Brazil using a medication called Epclusa to see if it helps more people get the care they need compared to traditional methods.
-
Helping young people who inject drugs start treatment for Hepatitis C
This study tests a new support program to help young adults who inject drugs start treatment for Hepatitis C and see if it works better than regular care.
-
Simplified hepatitis C testing with same-day treatment for people who inject drugs in Armenia, Georgia and Tanzania
This project will test whether a simplified pathway that starts hepatitis C treatment the same day after a quick antibody test helps people who inject drugs in Armenia, Georgia, and Tanzania get treated and cured faster than the usual antibody-plus-RNA pathway.
-
Point-of-care testing program for Hepatitis C screening
This study is testing if quick Hepatitis C tests done during a single visit can help more at-risk adults get diagnosed and start treatment faster.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.